Zymeworks Inc. (ZYME)
$25.07-1.03%Close
SELLBEAR · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.8B
- Beta
- 1.17
- P/E (TTM)
- -12.41
- Short % float
- 7.78%
- Days to cover
- 5.5
- SI change
- +7.1%
- 1W
- -2.26%
- 1M
- -6.63%
- vs SPY 1W
- -2.68%
- vs SPY 1M
- -8.69%
Industry peers
FMP comparable companies · ranked by market cap
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.21-0.14%
- CLDXSELLCelldex Therapeutics, Inc.$1.9BCRISISQ 5$29.30-4.01%
- IMNMSELLImmunome, Inc.$1.8BCRISISQ 18$19.31-8.20%
- XNCRSELLXencor, Inc.$1.8BRECOVERYQ 16$24.50-6.07%
- CTMXSELLCytomX Therapeutics, Inc.$538MCRISISQ 6$2.47-3.72%
- CBIOSELLCrescent Biopharma, Inc.$524MCRISISQ -1$14.12-10.72%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on ZYME?
- LOPJLB’s latest quantitative signal on Zymeworks Inc. (ZYME) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is ZYME in?
- Zymeworks Inc. (ZYME) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Zymeworks Inc. (ZYME) do?
- Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the bi…